Cargando…
Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK
BACKGROUND: Anti-tumour necrosis factor (anti-TNF) therapies are the most commonly used biologics for inflammatory bowel disease (IBD), but for patients with a comorbidity, newer agents may be a more appropriate treatment choice. AIMS: To investigate the impact of comorbidities in patients with IBD,...
Autores principales: | Akbar, Ayesha, Orchard, Tim, Powell, Nick, Selinger, Christian, tibbatts, Clare |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555136/ https://www.ncbi.nlm.nih.gov/pubmed/36250175 http://dx.doi.org/10.1136/flgastro-2021-101995 |
Ejemplares similares
-
Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK
por: Kapasi, Rukshana, et al.
Publicado: (2019) -
Aligning oral mesalazine treatment to health service priorities: guidance for nurses
por: Kemp, Karen, et al.
Publicado: (2014) -
Pelvic floor complaints in gastroenterology practice: results of a survey in the netherlands
por: Nicolai, Melianthe P J, et al.
Publicado: (2012) -
Results of the British Society of Gastroenterology supporting women in gastroenterology mentoring scheme pilot
por: Smith, Katherine H, et al.
Publicado: (2019) -
Gastroenterology 2021: from the heart of the COVID-19 pandemic
por: Tavabie, Oliver D, et al.
Publicado: (2021)